The US rollout of Alzheimer's drug Leqembi by Eisai and Biogen faces challenges due to doctors' skepticism about its effectiveness in treating the disease. Despite this, Biogen reports exceeding profit estimates with the drug's sales nearly tripling to $19 million.
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses. https://t.co/VLBSymsH3x
Biogen reported a quarterly profit that topped Wall Street estimates, helped by cost cutting, as the launch of its new Alzheimer's disease drug remained sluggish. https://t.co/GgMBqSgXgt https://t.co/GgMBqSgXgt
Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 7% before the bell. https://t.co/L4JCePNAS6 https://t.co/L4JCePNAS6
Biogen's Alzheimer's drug launch on 'steady pace' as logistical hurdles recede https://t.co/BFOyVbbpDb
Biogen’s $BIIB Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recede https://t.co/UnZfLZhQEm Also, Viehbacher's comments re: M&A
Biogen cost cuts drive profit beat, Alzheimer's drug sales jump https://t.co/BDhrbRrmHn https://t.co/hrDs5iXLfR
Biogen reports sales of Alzheimer’s drug exceeded expectations https://t.co/moqS5HgRym
$BIIB Biogen exceeded Q1 profit estimates, with shares rising nearly 4% premarket. The company highlighted significant growth in its Alzheimer's drug, which saw sales nearly triple to $19M.
Biogen $BIIB tops earnings expectations but revenue falls short https://t.co/jPXd2TGgex https://t.co/tFuvb4Ua3N
Biogen Stock Rises After Earnings and on Jump in Alzheimer’s Drug Sales https://t.co/ajyo747xgC
$BIIB (+6.6% pre) Biogen beats quarterly profit estimates, Alzheimer's drug sales jump https://t.co/sw0Ekax7Lv
Biogen’s stock climbs as first-quarter profit tops estimates, Alzheimer’s drug uptake improves https://t.co/N9eHIytlkr
$BIIB #Biogen tops profit estimates as cost cuts take hold, Leqembi launch picks up https://t.co/HKByKMn0Rg Earnings per share: $3.67 adjusted vs. $3.45 expected Revenue: $2.29 billion vs. $2.31 billion expected
Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition. https://t.co/CvQOfbQYvg https://t.co/CvQOfbQYvg
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up https://t.co/DPr1nPnAzq
$BIIB | Biogen Q1 Earnings: - Adj EPS $3.67 (Est. $3.44) 🟢 - Sales $2.291B (Est. $2.311B) 🔴 https://t.co/F3hLxe16nn
⚠️ BIOGEN BEATS QUARTERLY PROFIT ESTIMATES, ALZHEIMER'S DRUG SALES JUMP Full Story → https://t.co/IFqG9hk4Id Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition. https://t.co/eNh8AqjZVJ
Biogen reports first-quarter profit that beat Wall Street’s expectations, as the biotech giant cut costs and its new Alzheimer’s drug gained momentum https://t.co/L6n3IP8fKv
$BIIB | Biogen Q1 24 Earnings: - Adj EPS: $3.67 (est $3.44) - Revenue: $2.29B (est $2.31B) - Biogen Still Sees FY Adj EPS $15 To $16 (est $15.49)
No way, how come? Alzheimer's drug adoption in US slowed by doctors' skepticism $BIIB https://t.co/oZOvCeJiha
Nine months into the US launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi faces an unexpected hurdle to widespread use: a belief among some doctors that treating the memory-robbing disease is futile https://t.co/etPDBSxIP4
Alzheimer's drug adoption in U.S. slowed by doctors' skepticism https://t.co/310HNqUhCe
Alzheimer's drug adoption in US slowed by doctors' skepticism https://t.co/saCENIXeRa https://t.co/wtU3TKVfAB
⚠️ ALZHEIMER'S DRUG ADOPTION IN US SLOWED BY DOCTORS' SKEPTICISM Full Story → https://t.co/Rhbx8N4yPm Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use: an… https://t.co/QziN1Vol7t
Alzheimer’s drug Leqembi falls short of blockbuster status in faltering US rollout https://t.co/4mc7cgMtf1